Niels Høiby Selected Research

Ciprofloxacin (Cipro)

7/2022	Murine burn lesion model for studying acute and chronic wound infections.
1/2022	Lactoferricin-inspired peptide AMC-109 augments the effect of ciprofloxacin against Pseudomonas aeruginosa biofilm in chronic murine wounds.
1/2021	Adjunctive S100A8/A9 Immunomodulation Hinders Ciprofloxacin Resistance in Pseudomonas aeruginosa in a Murine Biofilm Wound Model.
1/2020	Synergistic effect of immunomodulatory S100A8/A9 and ciprofloxacin against Pseudomonas aeruginosa biofilm in a murine chronic wound model.
1/2020	Biofilms of Mycobacterium abscessus Complex Can Be Sensitized to Antibiotics by Disaggregation and Oxygenation.
1/2020	The evolutionary trajectories of P. aeruginosa in biofilm and planktonic growth modes exposed to ciprofloxacin: beyond selection of antibiotic resistance.
1/2016	The phenotypic evolution of Pseudomonas aeruginosa populations changes in the presence of subinhibitory concentrations of ciprofloxacin.
4/2011	Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
4/2010	Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Niels Høiby Research Topics

Disease

98	Infections 08/2022 - 05/2001
47	Cystic Fibrosis (Mucoviscidosis) 01/2022 - 12/2002
14	Wounds and Injuries (Trauma) 07/2022 - 05/2006
14	Persistent Infection 01/2018 - 11/2003
11	Inflammation (Inflammations) 01/2022 - 02/2009
5	Bacterial Infections (Bacterial Infection) 01/2022 - 09/2006
4	Pneumonia (Pneumonitis) 12/2020 - 06/2005
4	Burns 02/2018 - 01/2005
3	Respiratory Tract Infections (Respiratory Tract Infection) 03/2022 - 05/2006
3	Sepsis (Septicemia) 05/2019 - 05/2006
3	Lung Diseases (Lung Disease) 12/2018 - 11/2003
3	Urinary Tract Infections (Urinary Tract Infection) 04/2017 - 04/2002
3	Pseudomonas Infections 01/2016 - 04/2004
3	Foreign Bodies (Foreign Body) 03/2015 - 05/2012
2	Hypoxia (Hypoxemia) 01/2022 - 01/2014
2	Endocarditis 01/2022 - 01/2019
2	Bacteremia 11/2021 - 09/2015
2	AIDS-Related Complex (ARC) 05/2019 - 03/2016
2	Communicable Diseases (Infectious Diseases) 05/2019 - 08/2011
2	Sinusitis 04/2017 - 01/2013
2	Peritonitis 11/2009 - 11/2009
2	Body Weight (Weight, Body) 11/2009 - 08/2002
2	Cross Infection (Nosocomial Infection) 10/2008 - 09/2008
1	Latent Infection 01/2022
1	Asymptomatic Infections 01/2022
1	Cough 04/2019
1	Hypesthesia (Numbness) 04/2017

Drug/Important Bio-Agent (IBA)

56	Anti-Bacterial Agents (Antibiotics)IBA 08/2022 - 11/2003
16	AlginatesIBA 01/2018 - 08/2002
13	Immunoglobulin G (IgG)IBA 01/2022 - 05/2001
12	CytokinesIBA 01/2022 - 09/2003
11	AntibodiesIBA 01/2020 - 12/2002
9	Ciprofloxacin (Cipro)FDA LinkGeneric 07/2022 - 04/2010
7	Colistin (Coly-Mycin)FDA Link 01/2019 - 09/2008
7	Tobramycin (Nebcin)FDA LinkGeneric 01/2019 - 12/2005
6	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2017 - 06/2005
5	Secretory Immunoglobulin A (SIgA)IBA 04/2019 - 12/2012
5	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2017 - 06/2005
4	Oxygen (Dioxygen)IBA 01/2019 - 03/2011
3	Pharmaceutical PreparationsIBA 03/2022 - 08/2003
3	Immunoglobulin A (IgA)IBA 01/2020 - 01/2013
3	Imipenem FDA Link 01/2020 - 09/2007
3	Antigen-Antibody Complex (Immune Complex)IBA 01/2018 - 11/2010
3	DNA (Deoxyribonucleic Acid)IBA 04/2017 - 08/2009
3	Polymyxins (Polymyxin)IBA 05/2013 - 12/2011
3	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 07/2010 - 09/2003
2	MacrolidesIBA 07/2022 - 04/2004
2	Interleukin-2 (IL2)IBA 01/2022 - 12/2020
2	Peptide Hydrolases (Proteases)FDA Link 01/2022 - 04/2017
2	Peptides (Polypeptides)IBA 01/2022 - 01/2019
2	Azithromycin (Zithromax)FDA LinkGeneric 01/2021 - 01/2020
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2018 - 07/2016
2	EnzymesIBA 01/2017 - 09/2007
2	Proteins (Proteins, Gene)FDA Link 07/2016 - 07/2010
2	AntioxidantsIBA 03/2015 - 04/2012
2	Antimicrobial PeptidesIBA 02/2014 - 11/2009
2	AgarIBA 07/2013 - 11/2010
2	SolutionsIBA 06/2013 - 04/2012
2	IronIBA 01/2011 - 07/2010
2	Ceftazidime (Fortum)FDA LinkGeneric 04/2010 - 12/2002
2	Meropenem (Merrem)FDA LinkGeneric 04/2010 - 09/2007
2	plectasinIBA 11/2009 - 11/2009
2	Virulence Factors (Pathogenicity Factors)IBA 10/2007 - 05/2007
2	beta-Lactamases (beta-Lactamase)IBA 09/2007 - 12/2002
2	SulfonamidesIBA 11/2003 - 04/2002
1	Interleukin-5 (Interleukin 5)IBA 01/2022
1	Interleukin-4 (Interleukin 4)IBA 01/2022
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	CD40 Ligand (CD40L)IBA 01/2022
1	lactoferricin BIBA 01/2022
1	FibrinIBA 11/2021
1	IgYIBA 01/2021
1	Tigecycline (Tygacil)FDA Link 01/2020
1	Moxifloxacin (Avelox)FDA Link 01/2020
1	Kanamycin FDA Link 01/2020
1	Cefoxitin (Cefoxitin Sodium)FDA LinkGeneric 01/2020
1	Linezolid (Zyvox)FDA Link 01/2020
1	Amikacin (A.M.K)FDA LinkGeneric 01/2020
1	Sulfamethoxazole FDA LinkGeneric 01/2020
1	Rifampin (Rifampicin)FDA LinkGeneric 01/2020
1	Clarithromycin (Biaxin)FDA LinkGeneric 01/2020
1	Trimethoprim (Proloprim)FDA LinkGeneric 01/2020
1	PeptidomimeticsIBA 01/2019
1	Dabigatran FDA Link 01/2019
1	PeptoidsIBA 01/2019
1	Lysine (L-Lysine)FDA Link 01/2019
1	IntegrinsIBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 08/2018
1	thiocyanateIBA 01/2018
1	Sepharose (Agarose)IBA 11/2017
1	ChemokinesIBA 01/2017
1	SteroidsIBA 01/2017
1	ImmunosorbentsIBA 01/2017

Therapy/Procedure

18	Therapeutics 03/2022 - 12/2002
4	Lung Transplantation 01/2020 - 10/2005
3	Catheters 04/2017 - 10/2008
1	Critical Care (Surgical Intensive Care) 01/2022
1	Hyperbaric Oxygenation 01/2022
1	Immunomodulation 01/2021
1	Phage Therapy 01/2019